LONDON, April 23, 2015 /PRNewswire/ --
Edison Investment Research, a leading international investment research firm, announces the initiation of full coverage of Balda
Highlights of the analysis on Balda by Edison's healthcare analysts Hans Bostrom and Dr Mick Cooper are as follows:
Balda is a leading international supplier of moulded plastic solutions to manufacturers of medical and technical products, counting key industry leaders as its main clients. Its buy-and-build strategy targeting advanced medical plastics is supported by its vast cash resources resulting from the sale of its mobile telephony assets in 2012. Using DCF, we value Balda at €221m/€3.76 per share, of which financial reserves comprises 87%.
(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )
Balda is a German producer of precision plastic components for use in medical devices, eyewear and other industrial applications, such as irrigation, electronics and automotive. It acts mainly as an OEM component supplier with manufacturing in Germany and the US. Balda is looking to develop its own branded products and is likely to use its considerable financial resources to expand through acquisitions, more likely to be small private companies than divisions of larger companies, in our view. To download this report, please click here.
All reports published by Edison are available to download free of charge from its website http://www.edisongroup.com.
About Edison: Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (http://www.fsa.gov.uk/register/firmBasicDetails.do'sid=181584).
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
LinkedIn: http://www.linkedin.com/company/edison-investment-research
Twitter: http://www.twitter.com/Edison_Inv_Res
YouTube: http://www.youtube.com/edisonitv
For more information please contact:
Hans Bostrom: Edison Investment Research, +44(0)20-3681-2522
Dr Mick Cooper, Edison Investment Research, +44(0)20-3077-5734
healthcare@edisongroup.com
